Exploring a new immune checkpoint pathway in bladder cancer
A New Immune Checkpoint Pathway in Human Bladder Cancer
This study is exploring a new way to help treat bladder cancer by looking at a specific immune pathway, with the goal of creating better therapies for patients who currently have limited options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-10992120 on NIH RePORTER |
What this research studies
This research investigates a newly identified immune checkpoint pathway in bladder cancer, which has shown limited treatment options with existing therapies. The team aims to understand how this pathway operates at the cellular and molecular levels, particularly focusing on the KIR3DL3-HHLA2 interaction. By dissecting the mechanisms involved, they hope to develop innovative immunotherapies that could enhance treatment effectiveness for bladder cancer patients. The research involves collaboration among experts in immunology and urology to ensure a comprehensive approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with bladder cancer, particularly those who have not responded to existing therapies.
Not a fit: Patients with non-cancerous bladder conditions or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for bladder cancer patients, potentially improving survival rates.
How similar studies have performed: While the approach of targeting new immune checkpoints is promising, it is still relatively novel and has not been extensively tested in bladder cancer specifically.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Zang, Xingxing — Albert Einstein College of Medicine
- Study coordinator: Zang, Xingxing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.